{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:06:51Z","timestamp":1792076811987,"version":"4.4.0"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) has claimed the lives of millions of people worldwide since it first emerged. The impact of the COVID-19 pandemic on public health and the global economy has highlighted the medical need for the development of broadly acting interventions against emerging viral threats. Galidesivir is a broad-spectrum antiviral compound with demonstrated in vitro and in vivo efficacy against several RNA viruses of public health concern, including those causing yellow fever, Ebola, Marburg, and Rift Valley fever. In vitro studies have shown that the antiviral activity of galidesivir also extends to coronaviruses. Herein, we describe the efficacy of galidesivir in the Syrian golden hamster model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Treatment with galidesivir reduced lung pathology in infected animals compared with untreated controls when treatment was initiated 24 h prior to infection. These results add to the evidence of the applicability of galidesivir as a potential medical intervention for a range of acute viral illnesses, including coronaviruses.<\/jats:p>","DOI":"10.3390\/v14010008","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T01:08:09Z","timestamp":1640135289000},"page":"8","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Activity of Galidesivir in a Hamster Model of SARS-CoV-2"],"prefix":"10.3390","volume":"14","author":[{"given":"Ray","family":"Taylor","sequence":"first","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd. Suite 200, Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bowen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Demarest","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd. Suite 200, Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"DeSpirito","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd. Suite 200, Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airn","family":"Hartwig","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Bielefeldt-Ohmann","sequence":"additional","affiliation":[{"name":"School of Chemistry & Molecular Biosciences, St Lucia Campus, University of Queensland, Brisbane, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5143-6897","authenticated-orcid":false,"given":"Dennis M.","family":"Walling","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd. Suite 200, Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mathis","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd. Suite 200, Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarlagadda S.","family":"Babu","sequence":"additional","affiliation":[{"name":"BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd. Suite 200, Durham, NC 27703, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"ref_1","unstructured":"(2021, December 08). COVID-19 Map: Johns Hopkins Coronavirus Resource Center. Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","unstructured":"(2021, May 22). Center for Drug Evaluation Research Application Number: 214787Orig1s000: Summary Review, Available online: Accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214787Orig1s000Sumr.pdf."},{"key":"ref_4","unstructured":"(2021, September 10). Emergency Use Authorization for Bamlanivimab 700 mg and Etesevimab 1400 mg IV Administered Together, Center for Drug Evaluation and Research Review, Available online: https:\/\/www.fda.gov\/media\/146255\/download."},{"key":"ref_5","unstructured":"(2021, September 10). Emergency Use Authorization for Casirivimab and Imdevimab, Center for Drug Evaluation Research Review, Available online: https:\/\/www.fda.gov\/media\/144468\/download."},{"key":"ref_6","unstructured":"(2021, December 09). Pfizer\u2019s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2\/3 EPIC-HR Study. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate."},{"key":"ref_7","unstructured":"(2021, December 09). Merck and Ridgeback\u2019s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Available online: https:\/\/www.merck.com\/news\/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105180","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An update on the progress of galidesivir (BCX4430), a broad -spectrum antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eaau9135","DOI":"10.1126\/scitranslmed.aau9135","article-title":"A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques","volume":"12","author":"Lim","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.05.013","article-title":"Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters","volume":"156","author":"Westover","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430\u2014A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-020-02439-0","article-title":"Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach","volume":"18","author":"Aftab","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa644","article-title":"Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in a golden Syrian hamster model: Implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"ref_20","unstructured":"Bowen, R. Personal communication."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2016.04.003","article-title":"Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds","volume":"131","author":"Smee","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jviromet.2017.03.012","article-title":"Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties","volume":"246","author":"Smee","year":"2017","journal-title":"J. Virol. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.celrep.2021.108959","article-title":"Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-CoV02","volume":"35","author":"Dittmar","year":"2021","journal-title":"Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41541-021-00321-8","article-title":"Replicating bacterium-vectored vaccine expression SARS-CoV-2 membrane and nucleocapsid proteins protects against sever COVID-19-like disease in hamsters","volume":"6","author":"Jia","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ragan, I., Hartson, L., Pidcoke, H., Bowen, R., and Goodrich, R.P. (2020). Pathogen reduction of SARS-CoV-2 in plasma and whole blood using riboflavin and UV light. PLoS ONE, 15.","DOI":"10.1101\/2020.05.03.074971"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbrc.2021.03.096","article-title":"ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model","volume":"555","author":"Vandyck","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3389\/fimmu.2018.01946","article-title":"Treating influenza infection, from now and into the future","volume":"9","author":"Davidson","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1093\/ofid\/ofx163.697","article-title":"Efficacy of galidesivir against Ebola virus disease in rhesus monkeys","volume":"4","author":"Warren","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/1\/8\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:50:41Z","timestamp":1760169041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["v14010008"],"URL":"https:\/\/doi.org\/10.3390\/v14010008","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}